Drug intelligence / Profile preview

CRA_10991

Development stage: Unknown
Modality: Small Molecules

Overview

CRA_10991 is a small molecule compound belonging to the class of organic compounds known as 2-phenylindoles. Its chemical formula is C20H20ClN3O2. The compound has been studied for its ability to bind active site-directed serine proteases, with research indicating it forms short hydrogen bond arrays in the binding site. There is no evidence that it has reached advanced clinical development or approval for any therapeutic indication[1][2][4].

Other names: QXAURVOBXQBPAP-UHFFFAOYSA-N

Targets

PRSS1 (Trypsin family)

Beyond the preview

Go deeper on CRA_10991.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRA_10991.

Explore the full profile